Five papers worth your time — May 19, 2026

Four papers out of NEJM and one from The Lancet lead today's batch. The NEJM quartet covers a perioperative immunotherapy win in head and neck cancer, back-to-back Phase 3 trials in IPF, a liquid biopsy-guided switch strategy in breast cancer that earned an FDA advisory committee rebuke, and a definitive test of prehospital whole blood in trauma. The Lancet closes out the five with the first Phase 2b/3 biologic data in COPD that goes beyond eosinophil counts.

Journal: New England Journal of Medicine (IF ~96) · Phase 3 open-label RCT · Published 18 May 2026 · DOI 10.1056/NEJMoa2415434

Study design: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) were randomized 1:1 to 2 cycles of neoadjuvant pembrolizumab added to standard-of-care (surgery ± radiation ± chemotherapy) followed by adjuvant pembrolizumab, versus standard care alone. Primary endpoint: event-free survival (EFS).1

Key results: Addition of neoadjuvant and adjuvant pembrolizumab significantly improved event-free survival compared with standard care alone.2

Peer-review status: Published in NEJM; fully peer-reviewed.

Clinical implication: HNSCC is the sixth most common cancer globally, and a substantial fraction of patients present at locally advanced stage where locoregional cure rates remain poor. A phase 3 EFS benefit with a perioperative PD-1 blockade strategy — if OS data confirm the signal — would represent a meaningful shift in the neoadjuvant standard for this population. Toxicity data and OS follow-up will determine how quickly guideline bodies move; for now, this is the first positive perioperative immunotherapy RCT in HNSCC.

Author affiliation: Not confirmed in accessible records (NEJM full-text paywalled); multi-institutional trial.

Journal: New England Journal of Medicine (IF ~96) · Phase 3 RCTs (two trials) · Published 18 May 2026 · DOI 10.1056/NEJMoa2501488 · Presented at ATS 2026

Study design: Two independent, placebo-controlled Phase 3 trials (TETON-1 and TETON-2) evaluating inhaled treprostinil versus placebo in patients with idiopathic pulmonary fibrosis. Primary endpoint: change in forced vital capacity (FVC) from baseline to week 52.3

Key results: Inhaled treprostinil produced a smaller FVC decline than placebo over 52 weeks in both trials. TETON-1 results confirmed those of TETON-2. Cough and drug discontinuation were more frequent in the treprostinil arm.4

Peer-review status: Published in NEJM; fully peer-reviewed. Funded by United Therapeutics (lead author: S.D. Nathan).

Clinical implication: IPF carries a median survival of 2–5 years from diagnosis, and existing antifibrotics (nintedanib, pirfenidone) slow but do not halt disease. A vasodilatory agent improving FVC trajectories — replicated across two independent trials — opens a potential combination treatment path. The cough and discontinuation signal is clinically relevant: patient tolerability in this population is a meaningful constraint. Full quantitative effect sizes (absolute FVC change, HR for progression) were not available from accessible records; the NEJM full publication carries those figures.

Author affiliation: Lead author: Steven D. Nathan (United Therapeutics-sponsored; exact institutional affiliation not confirmed in accessible records).

Journal: New England Journal of Medicine (IF ~96) · Phase 3 RCT · Published 18 May 2026 · DOI 10.1056/NEJMoa2502929 · NCT04964934

Study design: SERENA-6 enrolled patients with ER-positive, HER2-negative advanced breast cancer receiving first-line aromatase inhibitor + CDK4/6 inhibitor. When an ESR1 mutation was detected by liquid biopsy (circulating tumor DNA), patients were randomized to switch the aromatase inhibitor to camizestrant — a next-generation selective estrogen receptor degrader and complete ER antagonist — or continue the aromatase inhibitor, with CDK4/6 inhibition continuing in both arms. Primary endpoint: progression-free survival.5

Key results: Camizestrant demonstrated a PFS benefit versus continued aromatase inhibitor among patients with ctDNA-detected ESR1 mutations.6 The FDA Oncologic Drugs Advisory Committee (ODAC) voted against approval, citing immature overall survival data.

Peer-review status: Published in NEJM; fully peer-reviewed. Funded by AstraZeneca.

Clinical implication: ESR1 mutations arise in roughly 40% of patients progressing on first-line aromatase inhibitor therapy and are a known driver of endocrine resistance. A liquid biopsy-triggered pre-emptive switch strategy is conceptually appealing — the SERENA-6 design tests whether catching the mutation early and switching before clinical progression matters. The PFS signal suggests it does. ODAC's rejection on OS immaturity follows the same logic that slowed several prior oncology approvals: PFS gains in HR+ breast cancer do not always convert to OS, and with the CDK4/6 backbone in both arms the survival curves may take several more years to separate. AstraZeneca will need to present OS data before a US approval path reopens. Exact PFS HRs and confidence intervals were not available from accessible records; the NEJM full publication carries those figures.

Author affiliation: AstraZeneca-sponsored; global multi-site trial.

Journal: New England Journal of Medicine (IF ~96) · Cluster-randomized Phase 3 trial · Published 18 May 2026 · DOI 10.1056/NEJMoa2602167 · Presented at ATS 2026

Study design: Pragmatic, multicenter, cluster-randomized trial. 44 air medical bases were assigned 2:1 to prehospital transfusion of type-O whole blood (up to 2 units) versus plasma plus packed red blood cells (component therapy). Primary endpoint: 30-day mortality. Patients with traumatic hemorrhage transported by air.7

Key results: Prehospital transfusion of whole blood did not result in lower 30-day mortality than component therapy. Outcomes did not differ by blood storage age.8 Lead author: J.L. Sperry.

Peer-review status: Published in NEJM; fully peer-reviewed.

Clinical implication: Whole blood for prehospital trauma resuscitation has gained significant momentum in military and civilian trauma systems over the past decade, largely on the basis of observational data and the physiological rationale of delivering a balanced 1:1:1 ratio of clotting factors, plasma, and red cells in a single product. TOWAR is the largest prospective test of that strategy. The null result on 30-day mortality — with no differential by storage age — will directly challenge the operational and cost arguments for stocking whole blood at air medical bases, which carry a higher logistical burden than pre-thawed plasma and packed cells. Whether the result extends to ground transport or damage-control surgery settings requires separate data.

Author affiliation: Lead author: Jason L. Sperry, MD (University of Pittsburgh; exact affiliation not confirmed in accessible records). Multi-site air medical trial.

Journal: The Lancet (IF ~168) · Phase 2b (ALIENTO) and Phase 3 (ARNASA) RCTs · Published 18 May 2026 · DOI 10.1016/S0140-6736(26)00637-9 · Companion editorial DOI 10.1016/S0140-6736(26)00924-4 · Presented at ATS 2026

Study design: Two randomized, double-blind, placebo-controlled trials published together. ALIENTO (Phase 2b) and ARNASA (Phase 3) evaluated astegolimab — a monoclonal antibody targeting the ST2 receptor/IL-33 pathway — in patients with COPD and frequent exacerbations, enrolled irrespective of baseline blood eosinophil count.9 Astegolimab produced a rapid and sustained reduction in blood eosinophil counts, providing in-vivo target engagement confirmation.10

Key results: Astegolimab demonstrated efficacy on exacerbation reduction in COPD. Precise annualized exacerbation rate ratios and confidence intervals were not available from accessible records; the Lancet full publication carries those figures.

Peer-review status: Published in The Lancet; fully peer-reviewed. The accompanying editorial described the results as "a major progress towards expanding precision treatments for a broader patient population and an important step in biologic therapy for COPD."11

Clinical implication: Current COPD biologics — dupilumab, tezepelumab — are positioned in patients with elevated eosinophil counts (typically ≥300 cells/μL), restricting eligible populations. Astegolimab's IL-33/ST2 mechanism sits upstream of eosinophil-driven inflammation and, crucially, these trials enrolled patients regardless of baseline eosinophil count. If confirmed at the full-data readout, this would meaningfully expand the biologic-eligible pool in COPD, the fourth leading cause of death globally. The eosinophil-lowering effect also provides a pharmacodynamic readout that may help identify responders in future trials.

Author affiliation: Genentech/Roche-sponsored trial (Genentech manufactures astegolimab); global multi-site.